gms | German Medical Science

73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

29.05. - 01.06.2022, Köln

Nimodipine pre-treatment protects auditory hair cells from cisplatin-induced cell death by upregulation of LMO4

Protektive Wirkung von Nimodipin bei Cisplatin-assoziierter Ototoxizität

Meeting Abstract

  • presenting/speaker Saskia Fritzsche - Universitätsklinikum Halle (Saale), Klinik und Poliklinik für Neurochirurgie, Halle (Saale), Deutschland
  • Justine Werner - Universitätsklinikum Halle (Saale), Klinik und Poliklinik für Neurochirurgie, Halle (Saale), Deutschland
  • Christian Strauss - Universitätsklinikum Halle (Saale), Klinik und Poliklinik für Neurochirurgie, Halle (Saale), Deutschland
  • Christian Scheller - Universitätsklinikum Halle (Saale), Klinik und Poliklinik für Neurochirurgie, Halle (Saale), Deutschland
  • Sandra Leisz - Universitätsklinikum Halle (Saale), Klinik und Poliklinik für Neurochirurgie, Halle (Saale), Deutschland

Deutsche Gesellschaft für Neurochirurgie. 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie. Köln, 29.05.-01.06.2022. Düsseldorf: German Medical Science GMS Publishing House; 2022. DocP156

doi: 10.3205/22dgnc469, urn:nbn:de:0183-22dgnc4699

Veröffentlicht: 25. Mai 2022

© 2022 Fritzsche et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objective: Ototoxicity is known as one of the main side effects of cisplatin treatment and limits the quality of life of tumor patients, which is already impaired by their disease and important for recovery. Since there is no established therapy at the current time, the aim of this study was focused on the relationship between the neuroprotective effect of nimodipine in relation to the expression of LMO4 and its central role in cell survival in cisplatin-associated cell damage to auditory cells.

Methods: The undifferentiated and differentiated immortalized cell lines UB/OC-1 and UB/OC-2 were used. To investigate the cytotoxic effect, the cell death rate was measured, after nimodipine pre-treatment and stress induction by cisplatin based on the activity of lactate dehydrogenase (LDH) in the supernatant of the cells. Furthermore, Western Blot were performed to investigate anti-apoptotic signalling that may be associated with reduced cytotoxic effect after nimodipine pre-treatment. In addition, the protein level of LMO4 and known interacting proteins, Akt, CREB and Stat3 were analysed. The impact of intracellular calcium concentration under nimodipine pre-treatment and stress induction by cisplatin was detected by the fluorescent dye Cal-520.

Results: The cytotoxic effect by cisplatin on hair cells is attenuated by nimodipine in a dose-dependent manner and led to a significant reduction of cell death up to 65 % (p<0.05) in undifferentiated cells and even after differentiation, a reduction of 40 % (not significant) was still visible. The study confirmed that LMO4 is downregulated by cisplatin. Whereas nimodipine pre-treatment counteracted this reduction, which is associated with increased activation of Akt, CREB, and Stat3 upon cisplatin application. A calcium dependence of the protective effect of nimodipine could not be demonstrated, rather, an increase of intracellular calcium under stress regardless of nimodipine pre-treatment was detected.

Conclusion: By reducing the side effects of cisplatin through nimodipine pre-treatment, a significant improvement in patients' quality of life and better utilization of the chemotherapeutic effect could be achieved. Not only in adults, but especially in children who suffer from a high rate of hearing loss.